KEYNOTE-522: Pembrolizumab + Chemotherapy in Early TNBC — Mobile Quick Reference

Save for clinic

📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications

🎯 Clinical Bottom Line

Adding pembrolizumab to neoadjuvant carboplatin-taxane/anthracycline-cyclophosphamide chemotherapy, followed by adjuvant pembrolizumab, significantly improved pathological complete response in previously untreated stage II–III triple-negative breast cancer. An early event-free survival signal was also observed. This regimen is now standard of care for this population regardless of PD-L1 status.

Key Result 1: pCR (ypT0/Tis ypN0, first 602 patients ITT) — 64.8% vs 51.2%, difference 13.6 percentage points (95% CI, 5.4 to 21.8; P<0.001)

Key Result 2: EFS (all 1174 patients ITT, 18 months) — 91.3% vs 85.3%, HR 0.63 (95% CI, 0.43 to 0.93; p not reported — boundary not crossed at interim)

Safety Signal: Immune-related adverse events of interest: 38.9% vs 18.3% (grade ≥3: 12.9% vs 1.8%). Adrenal insufficiency occurred exclusively with pembrolizumab (2.3%).

✅ Patient Eligibility

Must Have:

• Centrally confirmed triple-negative breast cancer (all foci)
• Previously untreated, nonmetastatic (T1c N1-2 or T2-4 N0-2)
• ECOG 0 or 1
• Adequate organ function
• PD-L1 testing NOT required for eligibility

Cannot Have:

• Active autoimmune disease requiring systemic treatment within 2 years
• Active or history of noninfectious pneumonitis
• Clinically significant cardiovascular disease
• Active infection requiring systemic therapy

💊 Dosing Quick Guide

Experimental Regimen

Neoadjuvant Phase 1 (12 weeks): Pembrolizumab: 200 mg IV Q3W Paclitaxel: 80 mg/m² weekly Carboplatin: AUC 5 mg/mL/min Q3W or AUC 1.5 mg/mL/min weekly

Neoadjuvant Phase 2 (12 weeks): Pembrolizumab: 200 mg IV Q3W Doxorubicin 60 mg/m² or Epirubicin 90 mg/m² + Cyclophosphamide 600 mg/m² Q3W

Adjuvant: Pembrolizumab: 200 mg IV Q3W for up to 9 cycles

Control Regimen

Same chemotherapy backbone with placebo replacing pembrolizumab in all phases.

Key Dose Modifications [2]

• Withhold pembrolizumab for grade ≥2 immune-mediated adverse events; resume after recovery to grade ≤1
• Permanently discontinue for grade 4 or recurrent grade 3 immune-mediated events
• Monitor thyroid function and morning cortisol; initiate hormone replacement as needed

Mechanism: Pembrolizumab is a humanized anti–PD-1 monoclonal antibody that blocks PD-1/PD-L1 interaction, releasing T cell–mediated antitumor immunity [2].

⚠️ Safety Snapshot

⚠️ Immune-related AEs of interest: Any grade 38.9% vs 18.3%, Grade ≥3 12.9% vs 1.8%

⚠️ Adrenal insufficiency: Any grade 2.3% vs 0%, Grade ≥3 1.3% vs 0% — pembrolizumab arm only

⚠️ Severe skin reaction: Any grade 4.4% vs 1.0%, Grade ≥3 3.8% vs 0.3%

Key safety metrics:

• Treatment-related deaths: 3 (0.4%) vs 1 (0.3%)
• Discontinuations due to AE: 23.3% vs 12.3%
• Serious treatment-related AEs (neoadjuvant): 32.5% vs 19.5%

📊 Key Numbers

Median follow-up: 15.5 months (range, 2.7 to 25.0)

Note: EFS had not crossed prespecified boundary at this interim. Only 104 of 327 expected events had occurred.

🔬 Key Comparator Context

Cross-trial comparisons are limited by differences in populations, designs, and endpoints.

🔍 Subgroups to Watch

Node positive: Diff 20.6 pp (95% CI, 8.9 to 31.9) — largest observed benefit Node negative: Diff 6.3 pp (95% CI, –5.3 to 18.2) — CI crosses zero Weekly carboplatin: Diff 18.4 pp (95% CI, 7.4 to 29.1) — larger benefit than Q3W Q3W carboplatin: Diff 7.7 pp (95% CI, –5.0 to 20.6) — CI crosses zero PD-L1 positive: Diff 14.2 pp (95% CI, 5.3 to 23.1) — significant PD-L1 negative: Diff 18.3 pp (95% CI, –3.3 to 36.8) — CI crosses zero, small n ECOG 1: Diff –2.6 pp (95% CI, –22.1 to 18.9) — very small subgroup, not interpretable

Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.

📋 Regulatory Status

⚠️ Verify current regulatory status before prescribing.

NCCN: Category 1 recommended regimen for T1c N1-2 or T2-4 N0-2 TNBC (neoadjuvant pembro + chemo → adjuvant pembro) [3]

⚡ Grey Zones

• Cannot isolate pembrolizumab benefit from carboplatin backbone — control arm also received carboplatin
• Unknown whether patients achieving pCR can safely omit adjuvant pembrolizumab
• BRCA-mutated subgroup not analyzed — unclear if benefit magnitude differs
• T1cN0 patients at lower boundary of eligibility — benefit–risk balance less clear
• Long-term immune-mediated toxicity (adrenal insufficiency, thyroid) not captured at 15.5 months follow-up

📖 Full Analysis

Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.

References

1. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810-821. doi:10.1056/NEJMoa1910549
2. Keytruda (pembrolizumab) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
4. Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031). Lancet. 2020;396(10257):1090-1100. doi:10.1016/S0140-6736(20)31953-X
5. Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer (GeparNuevo). Ann Oncol. 2019;30(8):1279-1288. doi:10.1093/annonc/mdz158